Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/58—[b]- or [c]-condensed
  • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06086—Dipeptides with the first amino acid being basic
  • C07K5/06095—Arg-amino acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides

Definitions

• This invention relates to therapeutic immunoconjugates, compositions that can be 5 utilized to make them, and methods of making and using such compositions and
• the natural products CC-1065 and the duocarmycins are potent cytotoxic agents that bind to the minor groove of DNA. They are characterized by a fused cyclopropyl ring 10 (dotted box in structures below) that is destabilized by conformational changes induced upon binding within the minor groove and reacts with a DNA adenine base in a ring-opening alkylation reaction. The damage to the DNA can be irreparable, leading to cell death.
• minor groove binding agent or "MGBA” will be used to refer to CC-1065/duocarmycin type compounds having the fused cyclopropyl ring or its seco form, although other types of DNA minor groove binding compounds are known.
• Immunoconjugates represent an area of high current interest in anti-cancer therapy.
• a drug moiety is conjugated (covalently linked) to an antibody whose antigen is uniquely expressed or overexpressed by a cancer cell ("tumor associated antigen").
• tumor associated antigen In binding to its antigen, the antibody functions as a targeting agent for delivering the drug moiety to the cancer cell with high specificity.
• the antigen can be a protein on the surface of the cancer cell.
• the antigen-immunoconjugate complex Upon binding of the antibody to the antigen, the antigen-immunoconjugate complex is internalized and eventually finds its way inside a vesicular body such as a lysosome, where the covalent linker between the drug moiety and the antibody is cleaved, liberating the drug moiety to exert its cytotoxic effect.
• the tumor associated antigen can be one that is secreted by tumor cells into the vicinal extracellular space.
• the covalent linker is designed such that cleavage is effected by a factor prevalent inside a lysosome but not in plasma.
• a factor prevalent inside a lysosome but not in plasma is the lower lysosomal pH, so that the covalent linker can be an acid-sensitive group such as a hydrazone.
• Another such factor is the generally higher intracellular concentration of glutathione, allowing for the cleavage of disulfide covalent linkers by a disulfide exchange mechanism.
• Yet another such factor is the presence of lysosomal enzymes such as cathepsin B, which can cleave peptidyl linkers designed to be preferred substrates (Dubowchik et al. 2002).
• MGBAs Their potency makes MGBAs attractive candidates for the drug moiety in an immunoconjugate.
• Illustrative disclosures relating to MGBAs and their use in immunoconjugates include: Boyd et al. 2008 and 2010; Chen et al. 2010; Gangwar et al. 2008; Ng et al. 2002, 2006a, 2006b, 2009a, 2009b, and 2010; and Sufi et al. 2010.
• the derivative By selecting a derivative that is cleaved inside a lysosome, the derivative functions as a prodrugging group and provides a safety factor: two cleavages, of the linker and of the prodrugging group, must occur before active cytotoxin is released.
• One such prodrugging group is a carbamate, which can be cleaved by lysosomal and/or cytosolic carboxyesterase as shown below.
• R a and R b represent generic radical groups.
• Seco form prodrugged Seco form convertible as carbamate (inactive) to cyclopropyl form
• Another prodrugging group that can be used with seco-MGBAs is a phosphate, in which case the cleaving enzyme is a phosphatase, found inside lysosomes and/or in the cytosol.
• Illustrative disclosures relating to phosphate prodrugging groups in seco-MGBAs include Boyd et al. 2010, Chen et al. 2009, Glazier 2003, King et al. 2011, Kutyavin et al. 1997, Ng et al. 2002, Zhao et al. 2002a and 2002b, and Zhao et al. 2010.
• An MGBA compound that has been extensively studied has the structure (A) (Boyd et al. 2008 and Sufi et al. 2010). It has a carbamate prodrugging group; a valine- citrulline (Val-Cit, recited in N-to-C direction, i.e., from the amino (N3 ⁇ 4) terminus to the carboxyl (CO2H) terminus) dipeptide linker, designed to be cleaved by cathepsin B (Dubowchik et al. 2002); and a maleimide group, for immunoconjugation by the Michael addition of an antibody sulfhydryl group.
• An immunoconjugate of compound (A) and an anti-CD70 antibody has been undergoing clinical trials.
• this invention provides an immunoconjugate comprising an antibody (or an antigen binding fragment thereof) and a phosphate-prodrugged seco-MGBA compound.
• the removal of the phosphate prodrugging group is independent of
• One embodiment is an immunoconjugate wherein a compound of the formula (I)
• X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof, is conjugated at the - ⁇ 3 ⁇ 4 group thereof via a peptidyl linker to an antibody or antigen binding fragment of such antibody.
• the antibody is a human monoclonal antibody that recognizes a human antigen selected from the group consisting of CD70, mesothelin, PSMA, CD19, glypican-3, B7H4, RG-1, CD22, and PTK7.
• a phosphate-prodrugged seco-MG A compound adapted for conjugation to an antibody or antigen binding fragment thereof.
• such a compound comprises a phosphate-prodrugged seco-MGBA moity, an enzymatically cleavable peptidyl linker, a spacer moiety, and a reactive functional group for attachment to an antibody or antigen-binding fragment thereof.
• One embodiment is represented by a compound of formula (II)
• X is a nucleophilically displaceable leaving group
• AA a and each AA b are independently selected from the group consisting of alanine, ⁇ -alanine, ⁇ -aminobutyric acid, arginine, asparagine, aspartic acid, ⁇ - carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
• n 0, 1, 2, 3, 4, or 5;
• Y is a spacer moiety
• Z is a reactive functional group capable of conjugation to an antibody
• a phosphate prodrugged compound that can be used to prepare immunoconjugates, as embodied by a compound of formula (I):
• Compound (I) wherein X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof.
• Compound (I) can be combined with a peptidyl linker, spacer, and reactive functional group as described above and then conjugated to an antibody or antigen-binding fragment thereof.
• a method of treating a cancer in a subject - preferably a human - suffering from such cancer comprising administering to the subject a therapeutically effective amount of an immunoconjugate of this invention.
• the cancer can be a cancer whose cells express an antigen selected from the group consisting of CD70, mesothelin, PSMA, CD 19, glypican-3, B7H4, RG-1, CD22, and PTK7.
• Examples of cancers that can be so treated include renal cancer, pancreatic cancer, ovarian cancer, lymphoma, colon cancer, mesothelioma, gastric cancer, lung cancer, prostate cancer, adenocarcinoma, liver cancer, and breast cancer.
• an immunoconjugate of this invention for the preparation of a medicament for the treatment of cancer.
• FIGS. 1A and IB in combination show the synthesis of a compound of this invention, having a maleimide reactive functional group.
• FIG. 2 shows the synthesis of another compound of this invention.
• FIGS. 3A through 3D in combination show the synthesis of yet another compound of this invention.
• FIGS. 4A through 4R compare the cell proliferation inhibitory properties of phosphate prodrugged immunoconjugates of this invention against those of carbamate prodrugged immunoconjugates, using a 3 H thymidine incorporation proliferation assay.
• test cell lines included the following human cancer cell lines: 786-0 (renal carcinoma), prostate specific membrane antigen (PSMA), HPAC (pancreatic cancer), OVCAR3 (ovarian cancer), Ramos (Burkitt's lymphoma), H226 (mesothelioma), N87 (gastric cancer), H292 (mucoepidermoid pulmonary carcinoma), HI 650 (adenocarcinoma), Hep 3b (hepatocellular carcinoma), Hep G2 (hepatocellular carcinoma), HCC-1954 (breast cancer), MDA-MB-468 (breast cancer), HCT1 16 (colon cancer) and H520 (lung cancer). Additionally, a mesothelin- expressing transfected CHO (Chinese hamster ovary) cell line was used.
• FIG. 5 depicts chromatographic traces showing the dephosphorylation of a phosphate prodrugged compound of this invention by human liver microsome enzymes.
• FIG. 6 is a plot of the amount of dephosphorylated product produced as a function of microsome concentration, over a period of one hour.
• FIG. 7 shows the synthesis of yet another compound of this invention, having an azide reactive functional group for conjugation to an antibody.
• FIG. 8 shows the synthesis of yet another compound of this invention, having a hydroxylamine reactive functional group for conjugation to an antibody.
• FIGS. 9A and 9B show in combination the synthesis of a compound of this invention, having a Leu-Ala-Leu tripeptide.
• FIGS. 10A and 10B show in combination the synthesis of a compound of this invention, having a Leu-Ile dipeptide.
• FIGS. 11A and 11B show in combination the synthesis of another compound of this invention.
• FIGS. 12A-12I show the results of various xenograft studies.
• Antibody means whole antibodies and any antigen binding fragment (i.e., "antigen-binding portion") or single chains thereof.
• a whole antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
• Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region comprising three domains, CHI, CH2 and CH3.
• Each light chain comprises a light chain variable region (VL or V k ) and a light chain constant region comprising one single domain, CL.
• the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved framework regions (FRs).
• CDRs complementarity determining regions
• Each VH and VL comprises three CDRs and four FRs, arranged from amino- to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
• the variable regions contain a binding domain that interacts with an antigen.
• the constant regions may mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
• An antibody is said to "specifically bind" to an antigen X if the antibody binds to antigen X with a KD of 5 x 10 ⁇ 8 M or less, more preferably 1 x 10 ⁇ 8 M or less, more preferably 6 x 10 ⁇ 9 M or less, more preferably 3 x 10 ⁇ 9 M or less, even more preferably 2 x 10 ⁇ 9 M or less.
• the antibody can be chimeric, humanized, or, preferably, human.
• the heavy chain constant region can be engineered to affect glycosylation type or extent, to extend antibody half-life, to enhance or reduce interactions with effector cells or the complement system, or to modulate some other property. The engineering can be accomplished by replacement, addition, or deletion of one or more amino acids or by replacement of a domain with a domain from another immunoglobulin type, or a combination of the foregoing.
• Antibody fragment and "antigen-binding portion” of an antibody mean one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody, such as (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab' fragment, which is essentially an Fab with part of the hinge region (see, for example, Abbas et al, Cellular and Molecular Immunology, 6th Ed., Saunders Elsevier 2007); (iv) an Fd fragment consisting of the V H and CHI domains; (v) an Fv fragment consisting of the VL and VH domains of a
• the two domains of the Fv fragment, VL and VH are encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv, or scFv); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
• Such single chain antibodies are also encompassed within the term "antigen-binding portion" or "antigen-binding fragment" of an antibody.
• an "isolated antibody” means an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds antigen X is substantially free of antibodies that specifically bind antigens other than antigen X).
• An isolated antibody that specifically binds antigen X may, however, have cross- reactivity to other antigens, such as antigen X molecules from other species.
• an isolated antibody specifically binds to human antigen X and does not cross- react with other (non-human) antigen X antigens.
• an isolated antibody may be substantially free of other cellular material and/or chemicals.
• “Monoclonal antibody” or “monoclonal antibody composition” means a preparation of antibody molecules of single molecular composition, which displays a single binding specificity and affinity for a particular epitope.
• Human antibody means an antibody having variable regions in which both the framework and CDR regions (and the constant region, if present) are derived from human germline immunoglobulin sequences. Human antibodies may include later modifications, including natural or synthetic modifications. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, “human antibody” does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
• Human monoclonal antibody means an antibody displaying a single binding specificity, which has variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences.
• human monoclonal antibodies are produced by a hybridoma that includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
• “Pharmaceutically acceptable salt” means a salt of a compound suitable for pharmaceutical formulation. Where a compound has one or more basic groups, the salt can be an acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methylsulfate, fumarate, benzoate, succinate, lactobionate, suberate, tosylate, and the like.
• an acid addition salt such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methylsulfate, fumarate, benzoate, succinate, lactobionate, suberate, tosylate, and the like.
• the salt can be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like.
• a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like.
• Polymorphic crystalline forms and solvates are also encompassed within the scope of this invention.
• specific examples of pharmaceutically acceptable salts include the sodium, potassium, and ammonium salts.
• composition of this invention is an immunoconjugate wherein a compound of the formula (I)
• X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof, is conjugated via a peptidyl linker to an antibody or an antigen binding fragment thereof.
• the conjugation preferably is through the 4-NH 2 group thereof.
• the peptidyl linker preferably is a dipeptide selected from Val-Cit, Phe-Cit, Phe-Lys, Val-Lys, Val-Glu, Val- Asp, Val-Ser, and Val-Gly, each dipeptide being recited in the N-to-C direction.
• the immunoconjugate has a structure represented by formula
• AA a , AA , m, and Y are as defined hereinabove in respect of formula (II),
• Ab represents an antibody or an antigen-binding fragment of an antibody, and n is 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt thereof.
• Preferred embodiments and/or combinations of AA a , AA b , m, Y, Ab, and n are described hereinbelow.
• a preferred immunoconjugate according to formula (Ilia) has a structure according to formula (Ilia')
• this embodiment has a Val-Cit dipeptide linker, with those skilled in the art understanding that in structural formula (Ilia') the dipeptide is drawn in a C-to-N orientation when read in a left to right direction.
• the immunoconjugate has a structure represented by formula (Illb)
• AA a , AA b , m, and Y are as defined hereinabove in respect of formula (II),
• Ab represents an antibody or an antigen-binding fragment of an antibody, and n is 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt thereof.
• Preferred embodiments and/or combinations of AA a , AA b , m, Y, Ab, and n are described hereinbelow.
• a preferred immunoconjugate according to formula (Illb) has a structure according to formula (Illb')
• each antibody can conjugate with more than one prodrugged seco-MGBA moiety, depending on the number of sites the antibody has available for conjugation and the experimental conditions employed.
• an immunoconjugate preparation may assay for a non-integer ratio of prodrugged seco-MGBA moieties per antibody ("substitution ratio" or "SR"), reflecting a statistical average.
• SR preferably is between 1 and 5, more preferably between 2.5 and 3.5.
• Another aspect of this invention is a compound adapted for conjugation to an antibody, represented by formula (II)
• AA a , AA b , m, Y, and Z are as previously defined, or a pharmaceutically acceptable salt thereof. Preferred embodiments and/or combinations of AA a , AA b , m, Y, and Z are described hereinbelow.
• a preferred embodiment according to formula (II) has the structure of formula (Ila)
• X is a nucleophilically displaceable group, preferably CI, Br, or tosylate, more preferably CI.
• AA a and each AA b are independently selected from the group consisting of alanine, ⁇ -alanine, ⁇ -aminobutyric acid, arginine, asparagine, aspartic acid, ⁇ -carboxyglutamic acid, citrulline (Cit), cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
• AA a and AA b are selected from the group consisting of arginine, aspartic acid, citrulline, glutamic acid, glutamine, glycine, histidine, lysine, phenylalanine, serine, threonine, tryptophan, tyrosine, and valine.
• the moiety -AA a -[AA b ] m - in formulae (II), (Ilia) and (Illb) represents a peptidyl linker where consecutive amino acids are joined by peptidyl bonds. It preferably is one that is cleavable by an intracellular or extracellular enzyme associated with the target cell.
• the enzyme can be, for example, cathepsin B, cathepsin E, legumain, or CD 10.
• the peptidyl linker preferably consists of one to six, more preferably one to three, and most preferably one to two amino acids.
• AA a preferably is Cit, Lys, Glu, Ser, He, Leu, or Thr, more preferably Cit or Lys, especially in combination with m equals 0, 1, or 2.
• m in formulae (II), (Ilia) and (Illb) is 0, 1, 2, 3, 4, or 5.
• m is 0, 1, or 2, more preferably 1.
• -AA a -[AA b ] m _ represents a single amino acid linker, a dipeptide linker, a tripeptide linker, and so forth, according to the value of m, with AA a being at the C-terminus and AA b at the N-terminus.
• AA a and AA b in combination form a dipeptide preferred dipeptides are Val-Cit, Phe-Cit, Phe-Lys, Val-Lys, Val-Glu, Val-Asp, Val-Ser, and Val-Gly, each dipeptide being recited in the conventional N- to-C direction.
• a Val-Cit dipeptide linker is especially preferred.
• the peptidyl linker consists of a single amino acid (i.e., m is 0), it preferably is Cit, Glu, Lys, or Ser, as taught in Chen et al. 2010, the disclosure of which is incorporated herein by reference.
• the foregoing dipeptide and single peptide linkers are cleavable by cathepsin B.
• Another enzyme that can be utilized for cleaving peptidyl linkers is legumain, a lysosomal cysteine protease that preferentially cleaves at Ala-Ala- Asn.
• the peptides Leu-Ala-Leu and Leu-Ile are designed to be cleaved by CD 10 and cathepsin E, respectively.
• Spacer Y in formulae (II), (Ilia), and (Illb) provides spatial separation between the prodrugged seco-MG A and the antibody (or antigen binding fragment thereof), lest the former sterically interfere with antigen binding by latter or the latter sterically interfere with cleavage of the peptidyl linker. Further, spacer Y can be used to confer increased solubility or decreased aggregation properties to the conjugates. Spacer Y can comprise one or more modular segments, which can be assembled in any number of combinations. Examples of suitable segments for spacer Y are:
• Spacer Y preferably provides a linear separation of from 5 to 20 atoms, more preferably from 5 to 15 atoms, between the amino acid AA a or AA b to which it is bonded and the reactive functional group Z.
• spacer Y is connected to AA a or AA b , as the case may be, by other than a carboxylic acyl group directly attached to the alpha-amino group of AA a or AA b .
• spacer Y is connected to the alpha-amino group of AA a or AA b , as the case may be, via a methylene group in spacer Y.
• Z is a reactive functional group capable of conjugation to an antibody.
• -Z is -NH 2 , -OH, -ONH 2 (hydroxylamine), -CO 2 H, -SH, cyclooctyne, azide (-N 3 ),
• An -OH group can be esterified with a carboxy group on the antibody, for example, on an aspartic or glutamic acid side chain.
• a -CO 2 H group can be esterified with a -OH group or amidated with an amino group (for example on a lysine side chain) on the antibody.
• a maleimide group can be conjugated with an -SH group on the antibody (e.g., from cysteine or from the chemical modification of the antibody to introduce a sulfhydryl functionality), in a Michael addition reaction.
• an -SH group on the antibody e.g., from cysteine or from the chemical modification of the antibody to introduce a sulfhydryl functionality
• N-hydroxysuccinimide group is functionally an activated carboxyl group and can conveniently be amidated by reaction with an amino group (e.g., from lysine).
• An -SH group is particularly useful for conjugation where the antibody has been modified to introduce a maleimide group thereto, in a Michael addition reaction that is the "mirror image" of that described above.
• Antibodies can be modified to have maleimide groups with N-succinimidyl 4-(maleimidomethyl)-cyclohexanecarboxylate (SMCC) or its sulfonated variant sulfo-SMCC, both reagents being available from Sigma-Aldrich.
• Azide and cyclooctyne are complementary functional groups that can effect conjugation via so-called "click chemistry," in which the azide adds across the strained alkyne bond of the cyclooctyne to form an 1,2,3-triazole ring.
• the azide can be the Z-group in a compound of formula (II) and the cyclooctyne can be situated on the antibody or antigen binding fragment thereof, or vice-versa.
• a cyclooctyne group can be provided by a DIBO reagent (available from Invitrogen/Molecular Probes, Eugene, Oregon).
• non-natural amino acids can be utilized, with the non-natural amino acid providing a functionality for conjugation with the reactive functional group.
• the non-natural amino acid p-acetylphenylalanine can be incorporated into an antibody, as taught in Tian et al, WO 2008/030612 A2 (2008).
• the ketone group in p-acetylphenyalanine can be a conjugation site by the formation of an oxime with a hydroxylamino reactive functional group.
• Other non-natural amino acids also can be incorporated using the ReCODETM technology of Ambrx, Inc. (La Jolla, California).
• the antibody preferably is an antibody against a tumor associated antigen, allowing the immunoconjugate to selectively or preferentially target cancer cells.
• antigens include: mesothelin, prostate specific membrane antigen (PSMA), CD 19, CD22, CD30, CD70, B7H4 (also known as 08E), protein tyrosine kinase 7 (PTK7), glypican-3, RGl, CTLA-4, and CD44.
• PSMA prostate specific membrane antigen
• CD 19 CD22
• CD30 CD70
• B7H4 also known as 08E
• PTK7 protein tyrosine kinase 7
• glypican-3 glypican-3
• RGl RGl
• CTLA-4 CTLA-4
• CD44 protein tyrosine kinase 7
• the antibody can be animal (e.g., murine), chimeric, humanized, or, preferably, human.
• the antibody preferably is monoclonal, especially
• Another aspect of the invention is a prodrugged compound of the formula (I)
• a compound of formula (I) can be conjugated to an antibody or an antigen-binding fragment thereof to make a therapeutically useful immunoconjugate by the employment of an appropriate linker, spacer, and reactive functional group, as discussed above.
• a preferred embodiment of formula (I) in which X is CI corresponds to a structure of formula (la):
• FIG. 4A shows the inhibitory activity of the two immunoconjugates on the proliferation of 786-0 cells, which are CD70-expressing human renal cancer cells.
• the conjugated antibody was 2H5, an anti-CD70 human monoclonal antibody.
• the compound (Ila) immunoconjugate not only had a lower EC5 0 (0.1000 nM versus 0.5725 nM) but also had a higher overall percentage of inhibition, as evidenced by the depth of its inhibition curve.
• the full sequence information for antibody 2H5 is disclosed in Coccia et al. 2010 and Terret et al. 2012b; the disclosures of which are incorporated herein by reference.
• V H CDR1, CDR2, and CDR3 and V K CDR1, CDR2, and CDR3 sequences for antibody 2H5 are given in SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively.
• FIG. 4B is a similar study, but using HPAC cells, which are mesothelin expressing human pancreatic cancer cells.
• the conjugated antibody was 6A4, an anti-mesothelin human monoclonal antibody.
• two different compound (Ha) conjugates were prepared, with substitution ratios of 1.25 and 3. (The cytotoxin concentrations on the X-axis are adjusted to reflect the substitution ratio.)
• FIG. 4B shows that the compound (A) immunoconjugate was essentially inactive, while the compound (Ha) immunoconjugates had approximately nanomolar ECso's. It is also noteworthy that the higher substitution ratio compound (Ila) immunoconjugate showed higher overall percentage of inhibition (deeper curve).
• V H CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 6A4 are given in SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 1 1, and SEQ ID NO: 12, respectively.
• FIG. 4C is another similar study, this time using CHO-meso cells, which are Chinese hamster ovary cells transfected to express mesothelin.
• the conjugated antibody was, again, 6A4.
• the compound (A) immunoconjugate was essentially inactive, while the compound (Ila) immunoconjugate had an EC5 0 of about 2 nM.
• FIG. 4D is yet another similar study, this time using OVCAR3 cells, which are mesothelin-expressing human ovarian cancer cells.
• the conjugated antibody was 6A4.
• the EC5 0 for the compound (Ila) immunoconjugate was approximately 1000 times lower than that for the compound (A) immunoconjugate.
• FIG. 4E is yet another similar study, this time using Ramos cells, which are CD19-expressing human Burkitt's lymphoma cells.
• the conjugated antibody was 21D4, an anti-CD 19 human monoclonal antibody.
• the disparity between the compound (A) and (Ila) immunoconjugates was again marked, with the former being essentially inactive while the latter had a sub-nanomolar EC5 0 .
• the full sequence information for antibody 21D4 is disclosed in King et al. 2010a and Rao-Naik et al. 2012; the disclosures of which are incorporated by reference.
• V H CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 21D4 are given in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.
• FIG. 4F is yet another similar study, this time with NCI-H226 (H226) cells, which are mesothelin-expressing human lung-derived mesothelioma cells.
• the conjugated antibody was, again, 6A4.
• compound (Ila) was conjugated to 2A10, which is a human monoclonal antibody against prostate specific membrane antigen ("PSMA").
• PSMA prostate specific membrane antigen
• the PSMA immunoconjugate had very little or no activity, as H226 cells do not express PSMA.
• the compound (A) immunoconjugate had similarly low or no activity.
• the two compound (Ila) immunoconjugates each had sub-nanomolar ECso's.
• the immunoconjugate with the higher substitution ratio exhibited a higher overall percentage of proliferation inhibition.
• the full sequence information for antibody 2A10 is disclosed in Huang et al. 2009 and Cardarelli et al. 2011 ; the disclosures of which are incorporated by reference.
• the VH CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 2A10 are given in SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively.
• FIG. 4G shows the activity of an immunoconjugate of anti-mesothelin antibody 6A4 and compound (Ila) against N87 human gastric carcinoma cells, which express mesothelin. A subnanomolar EC5 0 was observed.
• FIG. 4H shows the activity of immunoconjugates of antibody 6A4 and compound (Ila) at various substitution ratios (SRs) against H292 cells, which are mesothelin expressing human mucoepidermoid pulmonary carcinoma cells.
• SRs substitution ratios
• An immunoconjugate of anti-PSMA antibody 2A10 and compound (Ila) was used as a control.
• the EC5 0 values are shown in Table I, below. They show that there is a significant increase in potency when the SR is increased to about two or above.
• FIG. 41 shows a study similar to that of FIG. 4H, but against HI 650 cells, which are mesothelin expressing human adenocarcinoma cells.
• HI 650 cells which are mesothelin expressing human adenocarcinoma cells.
• the EC5 0 values are presented in Table II. Again, a jump in potency was noted at SR above about two.
• FIGS. 4 J and 4K are studies of immunoconjugates of this invention against two human hepatocellular carcinoma cell lines, Hep 3B and Hep G2, both of which express glypican-3.
• the potency of the anti-glypican-3 human monoclonal antibody 4A6 alone and when conjugated to compound (Ila) were compared, along with a control immunoconjugate of anti-CD70 antibody 2H5 and compound (Ila). (Neither Hep 3B nor Hep G2 cells express CD70.)
• the results show that the 4A6 immunoconjugate was very potent, about 1000X more active than the control CD70 immunoconjugate.
• the anti-glypican-3 antibody 4A6 alone was inactive. (The sequence information for antibody 4A6 is disclosed in Terrett et al.
• VH CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 4A6 are given in SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively.
• FIGS. 4L, 4M, and 4N are studies of the activity of an immunoconjugate of the anti-B7H4 human monoclonal antibody 2A7 and compound (Ila) against MDA-MB-468, HCC-1954, and OVCAR3 cell lines.
• the first two are human breast cancer cell lines, while the third one is a human ovarian cancer cell line, all of which express B7H4 but not CD70.
• An immunoconjugate of anti-PSMA antibody 2A10 and compound Ila was used as control. It can be seen from figures that there was some specific activity against the breast cancer cell lines but little or none against OVCAR3 cells. (The full sequence information for antibody 2A7 is disclosed in Korman et al. 2009 and Terrett et al.
• V H CDRl, CDR2, and CDR3 and V L CDRl, CDR2, and CDR3 sequences for antibody 2A7 are given in SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, and SEQ ID NO:36, respectively.
• FIG. 40 is a study of the activity of immunoconjugates of the anti-PSMA human monoclonal antibody 2A10 and the anti-RG-1 human monoclonal antibody 19G9, each conjugated to compound (Ila), against LNCap human prostate cancer cells, which express both PSMA and RG-1. Comparison data is provided for an immunoconjugate of anti- mesothelin antibody 6A4 and compound (Ila), as a control. It can be seen that both the PSMA and RG-1 conjugates were were effective, each with subnanomolar ECso's. (The full sequence information for antibody 19G9 is disclosed in King et al. 2011, the disclosure of which is incorporated herein by reference.
• VH CDRl, CDR2, and CDR3 and VL CDRl, CDR2, and CDR3 sequences for antibody 19G9 are given in SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42, respectively.
• FIG. 4P is a study of the activity of immunoconjugates of the anti-CD 19 human monoclonal antibody 21D4 and the anti-CD22 human monoclonal antibody 12C5, each conjugated to compound (Ila), against Ramos cells, which express both CD 19 and CD22. Comparison data is provided for immunoconjugates of anti-mesothelin antibody 6A4 and anti-CD70 antibody 2H5 compound (Ila). Both of the anti-CD 19 and anti-CD22 immunoconjugates were highly potent, each with subnanomolar ECso's. (The full sequence information for antibody 12C5 is disclosed in King et al. 2010b, the disclosure of which is incorporated by reference.
• V H CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 12C5 are given in SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48, respectively.
• FIG. 4Q shows the activity of an immunoconjugate of anti-PTK7 human monoclonal antibody 4D5 with compound Ila against HCT 116 cells, which are human colon carcinoma cells.
• the immunoconjugate had an EC5 0 of 1.87 nM, while a control immunoconjugate of the anti-PSMA antibody 2A10 was much less potent, with an EC50 of 951 nM.
• the full sequence information for antibody 4D5 is disclosed in Terrett et al. 2010a and Terrett et al. 2012a; the disclosures of which are incorporated by reference.
• VH CDRl, CDR2, and CDR3 and V K CDRl, CDR2, and CDR3 sequences for antibody 4D5 are given in SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, and SEQ ID NO:54, respectively.
• FIG. 4R shows the activity of an immunoconjugate of the aforementioned anti- PTK7 antibody 4D5 against H520 cells, which are human lung squamous cell carcinoma cells.
• the PTK7 immunoconjugate had an EC5 0 of 0.224 nM, while the control PSMA immunoconjugate again was much less potent, with an EC5 0 of 61.6 nM.
• immunoconjugates prodrugged with a phosphate group are not afflicted with such a problem, presumably because in most, if not all cells, the level of phosphatase activity is sufficiently high for efficient cleavage of the phosphate group.
• Immunoconjugates of this invention be used for treating diseases such as, but not limited to, hyperproliferative diseases, including: cancers of the head and neck which include tumors of the head, neck, nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas; cancers of the liver and biliary tree, particularly hepatocellular carcinoma; intestinal cancers, particularly colorectal cancer; ovarian cancer; small cell and non-small cell lung cancer (SCLC and NSCLC); breast cancer sarcomas, such as fibrosarcoma, malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, leiomysosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and alveolar soft part sarcoma; leuk
• compositions described herein will result in a reduction in the size or number of the cancerous growth and/ or a reduction in associated symptoms (where applicable).
• Pathologically practice of the method and use of compositions described herein will produce a pathologically relevant response, such as: inhibition of cancer cell proliferation, reduction in the size of the cancer or tumor, prevention of further metastasis, and inhibition of tumor angiogenesis.
• the method of treating such diseases comprises administering a therapeutically effective amount of an inventive combination to a subject. The method may be repeated as necessary.
• the cancer can be a cancer whose cells express CD70, mesothelin, CD19, glypican-3, B7H4, RG-1, CD22, or PTK7.
• the cancer being treated is renal cancer, pancreatic cancer, ovarian cancer, lymphoma, colon cancer, mesothelioma, gastric cancer, lung cancer, prostate cancer, adenocarcinoma, liver cancer, or breast cancer.
• Immunoconjugates of this invention can be administered in combination with other therapeutic agents, including antibodies, alkylating agents, angiogenesis inhibitors, antimetabolites, DNA cleavers, DNA crosslinkers, DNA intercalators, DNA minor groove binders, enediynes, heat shock protein 90 inhibitors, histone deacetylase inhibitors, immunomodulators, microtubule stabilizers, nucleoside (purine or pyrimidine) analogs, nuclear export inhibitors, proteasome inhibitors, topoisomerase (I or II) inhibitors, tyrosine kinase inhibitors, and serine/threonine kinase inhibitors.
• other therapeutic agents including antibodies, alkylating agents, angiogenesis inhibitors, antimetabolites, DNA cleavers, DNA crosslinkers, DNA intercalators, DNA minor groove binders, enediynes, heat shock protein 90 inhibitors, histone deacetylase inhibitors, immunomodulators, microtubule stabilizers, nucleoside (purine
• Specific therapeutic agents include adalimumab, ansamitocin P3, auristatin, bendamustine, bevacizumab, bicalutamide, bleomycin, bortezomib, busulfan, callistatin A, camptothecin, capecitabine, carboplatin, carmustine, cetuximab, cisplatin, cladribin, cytarabin, cryptophycins, dacarbazine, dasatinib, daunorubicin, docetaxel, doxorubicin, duocarmycin, dynemycin A, epothilones, etoposide, floxuridine, fludarabine, 5-fluorouracil, gefitinib, gemcitabine, ipilimumab, hydroxyurea, imatinib, infliximab, interferons, interleukins, ⁇ -lapachone, lenali
• Immunoconjugates of this invention can be formulated and administered using techniques conventional for biologic drugs.
• Formulations can include excipients, such as taught in Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th Ed.
• excipients include, without limitation, buffering agents (e.g., phosphates, acetate, tris(hydroxymethyl)aminomethane (Tris)), solubilizers and emulsifiers (e.g, polysorbate), preservatives (e.g., thimerosal, benzyl alcohol), salts (e.g., NaCl, KC1) chelators (e.g., EDTA), carbohydrates (e.g., sucrose, dextrose, maltose, trehalose), carriers (e.g., albumin), amino acids and their respective hydrochloride salts, citrates, sorbitol, dextran, and the like.
• buffering agents e.g., phosphates, acetate, tris(hydroxymethyl)aminomethane (Tris)
• solubilizers and emulsifiers e.g, polysorbate
• preservatives e.g., thimerosal,
• the immunoconjugates can be provided as lyophilized powders with or without excipients, which can then be dissolved in a medium such as sterile water for injection, sodium chloride solution for injection, or dextrose solution for injection, with or without additional excipients.
• a medium such as sterile water for injection, sodium chloride solution for injection, or dextrose solution for injection, with or without additional excipients.
• the immunoconjugate can be provided as a concentrated solution, optionally including excipients, which is then diluted to the desired concentration prior to administration.
• Alternative forms include dispersions, microemulsion, and liposomes.
• a pharmaceutical composition is suitable for intravenous ("IV"), intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
• parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
• Preferred modes of administration include IV infusion, IV bolus, subcutaneous, and intramuscular.
• a "therapeutically effective amount” preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom- free periods, or a prevention of impairment or disability due to the disease affliction.
• a "therapeutically effective amount” preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects.
• a therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject, which is typically a human but can be another mammal.
• Dosage regimens are adjusted to provide a therapeutic response. For example, a single dose may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
• Dosage unit form refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier. Devices such as prefilled syringes, two-chamber syringes, and autoinjectors can be used.
• the dosage will vary according to the disease being treated, patient traits such as age, gender, and genotype, and the stage of the treatment regimen. Typically, the dose can be from about 0.5 mg/kg to about 300 mg/kg.
• FIGS. 1A and IB combine to show the scheme for its synthesis.
• This Example relates to the synthesis of compound 14, also referred to herein as compound (la).
• the schematic for the synthesis is shown in FIG. 2.
• FIGS. 3A-3D show in combination the synthesis of compound 28, also referred to herein as compound (lib).
• compound (lib) also referred to herein as compound (lib).
• FIG. 3A shows the synthesis of a first intermediate compound 18.
• FIG. 3B shows the synthesis of a second intermediate compound 22.
• reaction mixture was stirred at RT overnight.
• the reaction mixture was diluted with EtOAc (600 mL) and the resultant solution was washed with a 2 C03 solution (5%, 200 mL), saturated aHC03 solution (1 x 200 mL), and brine (1 x 200 mL).
• the combined organic phases were dried over anhydrous MgS0 4 and concentrated to yield crude compound 21 as a yellow solid.
• FIG. 3C shows the synthesis of a third intermediate compound 25.
• FIG. 3D shows the completion of the synthesis of compound 28, also referred to herein as compound (lib).
• the amount of 2- iminothiolane to be added can be determined by a preliminary experiment and varies from antibody to antibody.
• a titration of increasing amounts of 2- iminothiolane is added to the antibody, and following incubation with the antibody for 1 h at RT 25 °C), the antibody is desalted into 50 mM pH 6.0 HEPES buffer using a
• Samples at a protein concentration of 0.5-1.0 mg/mL are typically used.
• the absorbance at 280 nm can be used to accurately determine the concentration of protein in the samples, and then an aliquot of each sample (0.9 mL) is incubated with 0.1 mL DTDP (5 mM stock solution in ethanol) for 10 min at RT. Blank samples of buffer alone plus DTDP are also incubated alongside. After 10 min, absorbance at 324 nm is measured and the number of thiol groups is quantitated using an extinction coefficient for thiopyridine of 19,800 M 1 .
• a thiolation level of about three thiol groups per antibody is desirable. For example, with some antibodies this can be achieved by adding a 15-fold molar excess of 2-iminothiolane followed by incubation at RT for 1 h. The antibody is then incubated with 2-iminothiolane at the desired molar ratio and then desalted into conjugation buffer (50 mM pH 6.0 HEPES buffer containing 5 mM glycine and 2 mM DTPA). The thiolated material is maintained on ice while the number of thiols introduced is quantitated as described above.
• conjugation buffer 50 mM pH 6.0 HEPES buffer containing 5 mM glycine and 2 mM DTPA
• the drug-linker moiety is added at a 3 -fold molar excess per thiol.
• the conjugation reaction is allowed to proceed in conjugation buffer also containing a final concentration of 5% dimethylsulfoxide (DMSO), or similar alternative solvent.
• DMSO dimethylsulfoxide
• the drug-linker stock solution is dissolved in 100% DMSO.
• the stock solution is added directly to the thiolated antibody, which has enough DMSO added to bring the final concentration to 10%, or pre-diluted in conjugation buffer containing a final concentration of 10% DMSO, followed by addition to an equal volume of thiolated antibody.
• the conjugation reaction mixture is incubated at RT for 2 h with stirring. Following incubation, the conjugation reaction mixture is centrifuged and filtered through a 0.2 ⁇ filter. Purification of the conjugate can be achieved through chromatography using a number of methods. In one method, the conjugate is purified using size-exclusion chromatography on a SEPHACRYLTM S200 column pre-equilibrated with 50 mM pH 7.2 HEPES buffer containing 5 mM glycine and 50 mM NaCl. Chromatography is carried out at a linear flow rate of 28 cm/h. Fractions containing conjugate are collected, pooled and concentrated. In an alternative method, purification can be achieved through ion-exchange chromatography.
• antibody-drug conjugate reaction mix is applied to an SP-SEPHAROSETM column pre-equilibrated in 50 mM pH 5.5 HEPES containing 5mM glycine.
• the antibody conjugate is eluted using a gradient of 0-1 M NaCl in equilibration buffer at pH 5.5.
• Relevant fractions containing the immunoconjugate are pooled and dialyzed against formulation buffer (50 mM pH 7.2 HEPES buffer containing 5 mM glycine and 100 mM NaCl).
• immunoconjugates of compound (Ila) were prepared with an anti-PSMA human monoclonal antibody (2A10, Huang et al. 2009 and Cardarelli et al. 201 1); an anti-mesothelin human monoclonal antibody (6A4, Terrett et al. 2009b), an anti-CD70 human monoclonal antibody (2H5, Terrett et al. 2009a), and an anti- CD ⁇ human monoclonal antibody (21D4, Rao-Naik et al. 2009).
• an anti-PSMA human monoclonal antibody (2A10, Huang et al. 2009 and Cardarelli et al. 201 1
• an anti-mesothelin human monoclonal antibody (6A4, Terrett et al. 2009b)
• an anti-CD70 human monoclonal antibody (2H5, Terrett et al. 2009a
• an anti- CD ⁇ human monoclonal antibody 21D4, Rao-Naik et al. 2009
• This example generally describes the procedure used to assay the antiproliferative activity of immunoconjugates of this invention.
• Human tumor cell lines were obtained from the American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, VA 20108, USA, and cultured according to ATCC instructions.
• CHO-Meso cells were generated by transfecting CHO cells with DNA containing human Mesothelin gene and selecting for stable clonnes expressing human Mesothelin. Cells were seeded at 1.0 x 10 4 cells/well in 96-well plates for 3 hr for 3 H thymidine assays, respectively. Serial dilutions (1 :3) of
• lysis buffer 25 mM NaOAc, 1 mM EDTA, 0.25 M sucrose, 0.1% Triton X-100, pH 5.5.
• the DNA of the cell lysate was hydrolyzed using BENZONASETM DNAse.
• Samples were first brought up in 1 mM MgS0 4 . After mixing, 2 ⁇ of BENZONASETM DNAse (neat) were added to each vial of lysate (4 ⁇ /mL, v/v, final concentration). Samples were then stored at RT for 15 min and then cooled on ice. For this step, successful DNAse activity was evidenced by appearance of flocculent precipitate. Samples were then spun at maximum speed in a microcentrifuge for 5 min to remove cellular debris. Supernatant was frozen at -70 °C for later use. Protein concentration of the lysate was determined using Pierce BCA Protein Determination methodology (Thermo Scientific). Samples in this study were found to contain 2.85 mg/mL protein.
• a 2000 ⁇ stock solution of the compound of formula (la) was prepared. Lysate was diluted to 2.1 mg/mL in lysate buffer. For reaction, 5 ⁇ ⁇ of the compound (la) stock was added to 95 ⁇ ⁇ of lysate. Final concentrations were 100 ⁇ compound (la) in lysate containing 2 mg/mL of protein. A buffer containing 25 mM NaOAc, 1 mM EDTA, 0.25 M sucrose, 0.1% Triton X 100, and 1 mM MgS0 4 provided buffering at pH 5.5. [00133] Negative controls were employed, with lysate buffer in place of cell lysate, with BENZONASETM DNAse and MgS0 4 also added.
• Test samples and controls were placed in a hot block set at 37 °C. At
• This example demonstrates the dephosphorylation of compound (la) by human and mouse liver microsome enzymes.
• Human liver microsomes derived from pooled liver sources were obtained from Xenotech (Part Number H-0630). They were supplied at a nominal protein concentration of 20 mg/mL in a 20% sucrose solution. Protein content was verified with BCA analysis using reagent from Thermo-Fisher .
• a 2000 ⁇ stock solution of the compound of formula (la) was prepared. For reactions, 95 ⁇ ⁇ of each microsome stock was allowed to equilibrate in a 37 °C hot block. A 5 ⁇ ⁇ aliquot of the compound (la) stock solution was then added to each reaction vial in precisely staggered 30 sec intervals. The final compound (la) concentration was 100 ⁇ . Samples were allowed to react at temperature for 1 hr, after which reaction was stopped with the addition of 100 ⁇ ⁇ of cold ethanol. Stop was performed again in precise 30 second intervals, such that each vial was allowed to react for exactly 1 hour. Samples were prepared in duplicate. Protein was allowed to precipitate on ice for 30 min. The supernatant was collected following centrifugation.
• FIG. 6 is a plot of the amount of compounds (IVa) and (IVb) produced from compound (la) after 60 min as a function of microsome concentration.
• the rate of production was essentially linear for microsome concentrations between 0.00156 and 0.0125 mg/mL. Using the data in this range, a rate for the production of compounds (IVa) and (IVb) of 0.0054 ⁇ mol/min/mg was calculated.
• Compound 30 (lie) has an azido reactive functional group, making it suitable for conjugation employing "click” chemistry.
• Compound 34 (lid) has a hydroxylamine reactive functional group, making it suitable for conjugation by oxime formation with an antibody modified to contain a ketone group, for example by the incorporation of the non-natural amino acid p-acetylphenylalanine.
• FIGS. 9A-9B in combination describe the synthesis of compound 48, also referred to herein as compound (He).
• FIGS. 11A-11B in combination describe the synthesis of compound 67, also referred to herein as compound (Ilg).
• FIGS. 12A-12I demonstrate the in vivo efficacy of immunoconjugates of this invention in xenograft studies with mice, against a variety of cancer types.
• OVCAR3 cell study Five million OVCAR3 ovarian cancer cells, resuspended in 0.1 mL phosphate buffered saline ("PBS”) plus 0.1 mL matrigel, were implanted
• PBS phosphate buffered saline
• FIG. 12A shows that, against OVCAR3 cells, immunoconjugates of anti-mesothelin antibody 6A4 with compound (Ila) suppressed tumor growth, especially at the higher dosage of 0.314 ⁇ /kg of cytotoxin. Comparative data for the corresponding immunoconjugate of the anti-CD 19 antibody 21D4 is also presented, as an isotype control.
• N87 cell study Two and a half million N87 gastric tumor cells, resuspended in 0.1 mL PBS plus 0.1 mL matrigel, were implanted subcutaneously at the flank region of SCID mice. Tumor measurements started 12 days later, and mice were randomized into groups of 7 mice each with average tumor sizes of 1 10 mm 3 estimated by LWH/2 of tumors. At 14 days post tumor implantation, mice were dosed intraperitoneally singly with testing compounds.
• FIG. 12B shows that, against N87 cells, an immunoconjugate of anti-mesothelin antibody 6A4 with compound (Ila) strongly inhibits tumor growth. Comparative data for formulation buffer alone or an immunoconjugate of anti-CD 19 antibody 21D4 and compound (Ila) are presented, the latter as an isotype control.
• H226 cell study Five million H226 mesothelioma cells, resuspended in 0.1 mL PBS plus 0.1 mL matrigel, were implanted subcutaneously at the flank region of SCID mice. Tumor measurements started 14 days later, and mice were randomized into groups of 9 mice each with average tumor sizes of 1 10 mm 3 estimated by LWH/2 of tumors. At 15 days post tumor implantation, mice were dosed intraperitoneally singly with testing compounds.
• FIG. 12C shows the dose-dependent effect of an immunoconjugate of anti-mesothelin antibody 6A4 and compound (Ila) on tumor growth. The SR was 3.6 in each instance.
• FIG. 12D shows the tumor inhibition by an immunoconjugate of anti-mesothelin antibody 6A4 and compound (Ila). Comparative data for a vehicle control and an immunoconjugate of anti-CD 19 antibody 21D4 and compound (Ila) are presented, the latter as an isotype control.
• Hep 3B cell study Four million Hep 3B liver tumor cells, resuspended in 0.1 mL PBS plus 0.1 mL matrigel, were implanted subcutaneously at the flank region of SCID mice. Tumor measurements started 10 days later, and mice were randomized into groups of 7 mice each with average tumor sizes of 90 mm 3 estimated by LWH/2 of tumors. At 1 1 days post tumor implantation, mice were dosed intraperitoneally singly with testing compounds.
• FIG. 12E shows the dose-dependent tumor growth inhibitory effect of an immunoconjugate of anti-glypican 3 antibody 4A6 and compound (Ila). The strongest effect was seen with a dose of 0.1 ⁇ /kg. Comparative data for vehicle alone, antibody 4A6 alone, or an immunoconjugate of anti-glypican 3 antibody 4A6 and compound (Ila). The strongest effect was seen with a dose of 0.1 ⁇ /kg. Comparative data for vehicle alone, antibody 4A6 alone, or an immunoconjugate of anti-glypican 3
• FIG. 12F is a graph from the same study, but demonstrating the ability of the antibody 4A6-compound (Ila) immunoconjugate to alleviate tumor-associated cachexia. Data for the anti-CD 19 -compound (Ila) immunoconjugate is also presented showing that the anti-CD 19 conjugate, while it reduces tumor growth (per FIG. 12E), it does not alleviate cachexia (per FIG. 12F).
• FIG. 12G shows the tumor growth inhibition by an immunoconjugate of anti-PSMA antibody 2A10 and compound (Ila), compared to formulation buffer and an immunoconjugate of anti-CD 19 antibody 21D4 and compound (Ila) as isotype control.
• FIG. 12H shows another set of results from the same study, with an immunoconjugate of anti-RG- 1 antibody 19G9 and compound (Ila), with an isotype control of an anti-CD 19
• FIG. 121 shows the tumor growth inhibitory effect by immunoconjugates of anti-mesothelin antibody 6A4, anti-CD 19 antibody 21D4, anti-CD22 antibody 12C5, and anti-CD70 antibody 1F4, each with compound (Ila).
• V H CDR1, CDR2, and CDR3 and V K CDR1, CDR2, and CDR3 sequences for antibody 1F4 are given in SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60, respectively.
• Glazier WO 03/000201 A2 (2003).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Cell Biology (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Reproductive Health (AREA)
• Pulmonology (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• General Chemical & Material Sciences (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46172969

Family Applications (1)

Country Status (23)

Cited By (27)

Families Citing this family (35)

Citations (32)

Family Cites Families (3)

• 2012
  • 2012-05-22 US US13/477,219 patent/US8852599B2/en active Active
  • 2012-05-24 WO PCT/US2012/039312 patent/WO2012162482A1/en not_active Ceased
  • 2012-05-24 AU AU2012258750A patent/AU2012258750B2/en not_active Ceased
  • 2012-05-24 SG SG2013085048A patent/SG195011A1/en unknown
  • 2012-05-24 PE PE2013002713A patent/PE20141480A1/es not_active Application Discontinuation
  • 2012-05-24 BR BR112013029764A patent/BR112013029764A2/pt not_active Application Discontinuation
  • 2012-05-24 EA EA201391754A patent/EA024844B1/ru not_active IP Right Cessation
  • 2012-05-24 EP EP12724065.3A patent/EP2714092B1/en not_active Not-in-force
  • 2012-05-24 ES ES12724065T patent/ES2814798T3/es active Active
  • 2012-05-24 MX MX2013013402A patent/MX336806B/es active IP Right Grant
  • 2012-05-24 AR ARP120101857A patent/AR086568A1/es unknown
  • 2012-05-24 CN CN201280025332.4A patent/CN103561772B/zh not_active Expired - Fee Related
  • 2012-05-24 PH PH1/2013/502189A patent/PH12013502189A1/en unknown
  • 2012-05-24 KR KR1020137033963A patent/KR102070464B1/ko not_active Expired - Fee Related
  • 2012-05-24 CA CA2837327A patent/CA2837327C/en not_active Expired - Fee Related
  • 2012-05-24 JP JP2014512101A patent/JP6105566B2/ja not_active Expired - Fee Related
  • 2012-05-25 TW TW101118845A patent/TW201300401A/zh unknown
  • 2012-05-25 UY UY0001034100A patent/UY34100A/es unknown
• 2013
  • 2013-11-15 MA MA36439A patent/MA35153B1/fr unknown
  • 2013-11-17 IL IL229477A patent/IL229477A/en active IP Right Grant
  • 2013-11-26 CL CL2013003393A patent/CL2013003393A1/es unknown
  • 2013-12-11 CO CO13289636A patent/CO6831975A2/es not_active Application Discontinuation
  • 2013-12-20 ZA ZA2013/09669A patent/ZA201309669B/en unknown
• 2014
  • 2014-08-21 ZA ZA2014/06168A patent/ZA201406168B/en unknown
  • 2014-08-28 US US14/471,096 patent/US9186416B2/en active Active
• 2017
  • 2017-02-02 JP JP2017017666A patent/JP6359133B2/ja not_active Expired - Fee Related

Patent Citations (40)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events